Prairiewood Capital LLC Has $378,000 Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Prairiewood Capital LLC reduced its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 4.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 10,973 shares of the company’s stock after selling 469 shares during the quarter. Prairiewood Capital LLC’s holdings in Harmony Biosciences were worth $378,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in shares of Harmony Biosciences by 13.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after purchasing an additional 112,197 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock valued at $26,416,000 after buying an additional 140,690 shares during the period. Millennium Management LLC lifted its position in shares of Harmony Biosciences by 51.6% in the second quarter. Millennium Management LLC now owns 307,420 shares of the company’s stock valued at $9,275,000 after buying an additional 104,691 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock worth $9,220,000 after acquiring an additional 181,092 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock worth $9,217,000 after acquiring an additional 93,622 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Insider Activity

In related news, insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $40.47, for a total value of $869,943.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Up 1.3 %

HRMY opened at $39.05 on Tuesday. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of 18.51, a P/E/G ratio of 0.49 and a beta of 0.78. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a twelve month low of $28.14 and a twelve month high of $41.61. The company has a 50-day simple moving average of $34.46 and a 200 day simple moving average of $34.96.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same quarter last year, the business posted $0.63 EPS. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. Analysts predict that Harmony Biosciences Holdings, Inc. will post 2.42 EPS for the current fiscal year.

Analysts Set New Price Targets

HRMY has been the subject of a number of research analyst reports. Mizuho lifted their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, October 10th. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Harmony Biosciences in a research note on Thursday, January 16th. Raymond James restated an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Cantor Fitzgerald increased their target price on Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $52.00 price objective on shares of Harmony Biosciences in a report on Monday, January 13th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.